UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
-------------------
For the month of November 2004
Commission File Number: 001-31368
SANOFI-AVENTIS
(Translation of registrant's name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): _____
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82-________
On November 29, 2004, Sanofi-Aventis (formerly known as Sanofi-Synthelabo)
issued the press release attached hereto as Exhibit 99.1 and incorporated herein
by reference.
EXHIBIT LIST
EXHIBIT NO. DESCRIPTION
----------- -----------
Exhibit 99.1 Press Release, dated November 29, 2004, announcing that
ELOXATIN(TM) (oxaliplatin for injection) based therapy
combined with bevacizumab (AVATIN(TM)) significantly improves
survival in patients with advanced colorectal cancer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Dated: November 30, 2004 SANOFI-AVENTIS
By: /s/ Jean-Claude Leroy
--------------------------------
Name: Jean-Claude Leroy
Title: Senior Vice President &
Chief Financial Officer
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
----------- -----------
Exhibit 99.1 Press Release, dated November 29, 2004, announcing that
ELOXATIN(TM) (oxaliplatin for injection) based therapy
combined with bevacizumab (AVATIN(TM)) significantly improves
survival in patients with advanced colorectal cancer.